Pivagabine - CeNeRx BioPharma

Drug Profile

Pivagabine - CeNeRx BioPharma

Alternative Names: CXB 722

Latest Information Update: 28 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CeNeRx BioPharma
  • Class Aminobutyric acids; Antidepressants
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Depressive disorders

Most Recent Events

  • 28 Jun 2013 Discontinued - Phase-II for Anxiety disorders in USA (PO)
  • 28 Jun 2013 Discontinued - Phase-II for Depressive disorders in USA (PO)
  • 09 Jan 2009 CeNeRx completes a phase I trial in Healthy volunteers in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top